Regulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech Summit
Rhea-AI Summary
Regulus Therapeutics (Nasdaq: RGLS), a biopharmaceutical company specializing in microRNA-targeted medicine development, has announced its participation in the 2025 Oppenheimer Innovation on the Island Biotech Summit.
CEO Jay Hagan will deliver a presentation on Wednesday, April 9th at 11:32 a.m. ET. Investors and interested parties can access both the live event and replay through the company's investor relations website at https://ir.regulusrx.com/events. The presentation recording will remain accessible for 90 days following the event.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, RGLS gained 12.00%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
The live event and replay of the presentation will be available under "Events and Presentations" through the investor relations section of the Company's website at https://ir.regulusrx.com/events and archived for 90 days following the presentation date.
About Regulus
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a pipeline complemented by a rich intellectual property estate in the microRNA field. Regulus maintains its corporate headquarters in San Diego, CA.
View original content to download multimedia:https://www.prnewswire.com/news-releases/regulus-therapeutics-to-present-at-the-2025-oppenheimer-innovation-on-the-island-biotech-summit-302417580.html
SOURCE Regulus Therapeutics Inc.